1. Scrip

Santhera Finds ‘Elegant Solution’ For Its Finances With Catalyst DMD Drug Deal

US Rights To Vamorolone Licensed For $90m Upfront

 
• By Kevin Grogan

The Swiss rare diseases firm Santhera has signed a licensing deal for its Duchenne muscular dystrophy drug vamorolone, which could be launched in both the US and the EU by the end of the year, paying off short-term debt and cleaning up the balance sheet.

Eklund_Dario_1200
Dario Eklund • Source: Santhera

With regulatory decisions imminent on both sides of the Atlantic for vamorolone, Santhera Pharmaceuticals has secured a North America partner for the closely watched Duchenne muscular dystrophy (DMD) therapy while banking a healthy upfront payment.

The Swiss group has signed a license and collaboration agreement for vamorolone with Catalyst Pharmaceuticals, Inc. covering the US,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

More from Scrip

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.